Real-time · AI · Cross-signal
Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on Personalis and Tempus AI — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Personalis and Tempus Expand Collaboration to Bring Ultra-Sensitive MRD Testing to Market
Aug 16, 2024•almost 2 years ago
Contract Type
partnership
FremontBiotechnologyHealth CareDescription
Personalis, Inc. and Tempus AI, Inc. have announced an expanded commercial relationship to bring ultra-sensitive MRD testing to the market. This expansion includes Tempus exercising existing warrants to purchase 9.2 million shares of common stock and an additional purchase of 3.5 million shares at a price per share of $5.07, resulting in a total investment of approximately $36 million in Personalis
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months